SecBot SecBot

SNDX

Syndax Pharmaceuticals Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001395937 Biotech & Drug Discovery
$9.13 −0.32 (−3.39%)
Nov 16 4:00 PM ET · prev $9.45
Market cap
$858.5M
Small cap
Consensus
Buy
94% Buy or better · 18 analysts
Median target
$36.00
+294% · range $17.00–57.00
1 year
−46.9%
from $17.18 · Nov 17
30 days
−30.3%
from $13.09
52-week range
$9.13–25.15
at the low
Avg volume 20D
4.02M
Nov 4 spike 15.06M
Short interest
18.92M
≈21.0% of shares · +5.1%
Days to cover
6.4
at average volume
Insider net
−$2.9M
0 buyers · 4 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
13
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $2.9M.

  • InstitutionsMIXED

    Q3 2026: 23 added (1 new), 20 trimmed or exited.

  • AnalystsBULLISH

    17 of 18 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +5.1% to 18.92M shares. 6.4 days to cover, ≈21.0% of shares.

  • TrendDOWNTREND

    39% below its 50-day average. New closing low $9.13 on Nov 16.

Who's buying

13F· Q3 2026
1
new positions
1
exit
FundMoveSharesValue
Aberdeen Group plcNEAR_EXIT80,319$36.6M
FRANKLIN TEMPLETON INCADD3,485,448$36.4M
LOOMIS SAYLES & CO L PADD1,335,828$25.1M
UBS Group AGTRIM1,145,735$21.5M
Nuveen, LLCTRIM857,898$16.1M
HRT FINANCIAL LPADD611,614$11.5M
Jump Financial, LLCADD530,466$10.0M
RENAISSANCE TECHNOLOGIES LLCTRIM192,071$3.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 94% rate it Buy or better
Strong Buy7Buy10Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +294%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 3, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 21, 2026UBS
MAINTAIN
MAINTAINBuy
Aug 11, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 5, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.9M
sold · 4 insiders
DateInsiderTypeValue
Nov 9, 2026
Ondrey Aaron
Chief Financial Officer
Nov 9, 2026
AWARD$2.6M
Oct 29, 2026
Podlesak Dennis
Director
Oct 29, 2026
SELL$113.7K
Oct 29, 2026
Podlesak Dennis
Director
Oct 29, 2026
EXERCISE$94.5K
Jul 8, 2026
Metzger Michael A
Chief Executive Officer
Jul 8, 2026
SELL$784.8K
Jul 8, 2026
Metzger Michael A
Chief Executive Officer
Jul 8, 2026
EXERCISE$206.6K
Jun 12, 2026
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 12, 2026
EXERCISE$431.7K
Jun 12, 2026
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 12, 2026
SELL$566.6K
Jun 11, 2026
Botwood Nicholas A.J.
Head of R&D, CMO
Jun 11, 2026
EXERCISE$311.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$2.13-$2.24–-$1.96-9.0%$316.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
18,920,163
shares short
+5.1%
vs prior settlement
6.4
days to cover
≈21.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 Clinical trial readout
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
Aaron Ondrey filed a Form 3 initial statement of beneficial ownership after becoming Chief Financial Officer of Syndax…
3 · Impact 1/10
Nov 10, 2026 SEC
State Street Corp filed a Schedule 13G disclosing a 5.2% passive stake in Syndax Pharmaceuticals as of September 30…
SC 13G · Impact 3/10
Nov 9, 2026 SEC
Syndax Pharmaceuticals issued a press release announcing an inducement stock option award of 270,000 shares to its new…
PRESS-RELEASE · Impact 2/10
Nov 9, 2026 Insider
Ondrey Aaron was granted 270,000 shares
Chief Financial Officer @ $9.55 ($2.6M)
Oct 29, 2026 Insider
Podlesak Dennis sold 8,000 shares
Director @ $14.21 ($113.7K)
Oct 29, 2026 Insider
Podlesak Dennis acquired via exercise 8,000 shares
Director @ $11.81 ($94.5K)
Sep 30, 2026 Inst.
Aberdeen Group plc · NEAR_EXIT
80,319 shares ($36.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Trial readout
🔒 Fresh data, subscribers only
Nov 16, 2026
Clinical Trial
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2 · COMPLETED
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or…
Nov 9, 2026
Earnings
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative…
Nov 5, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the…

SecBot reports

13 filings · 3 press releases · 1 bullish · 0 bearish · 12 neutral
All SNDX filing & press-release reports (16)